Pfizer Limited Q1 FY27 Financial Results Disclosure

Board Approval Details

The Board of Directors approved the financial results at their meeting held on July 28, 2026, that commenced at 11:30 a.m. and concluded at 1:35 p.m.

Auditor Review

The financial results were subject to limited review by statutory auditors B S R & Co. LLP, who issued an unmodified limited review report dated July 28, 2026. The report notes that the figures for the three months ended March 31, 2026, are balancing figures between audited full-year figures and published year-to-date figures up to the third quarter of previous financial year.

Financial Performance Highlights (₹ in crore except EPS)

Quarter Ended June 30, 2026 (Q1 FY27) - Unaudited:

  • Revenue from operations: ₹653.17 crore
  • Other income: ₹44.84 crore
  • Total income: ₹698.01 crore
  • Total expenses: ₹421.33 crore
  • Profit before tax and exceptional items: ₹276.68 crore
  • Exceptional items: Nil
  • Profit before tax: ₹276.68 crore
  • Tax expense: ₹72.21 crore (Current tax: ₹70.93 crore, Deferred tax: ₹1.28 crore)
  • Net profit for the period: ₹204.47 crore
  • Other comprehensive income (net of taxes): (₹0.54) crore
  • Total comprehensive income: ₹203.93 crore
  • Earnings per share (Basic and Diluted): ₹44.69
  • Earnings per share before exceptional items: ₹44.69
  • Paid-up equity share capital: ₹45.75 crore (Face value ₹10 per share)

Comparative Performance:

  • Revenue from operations increased 8.3% YoY from ₹603.05 crore in Q1 FY26
  • Net profit increased 6.6% YoY from ₹191.75 crore in Q1 FY26
  • Sequential quarter (Q4 FY26) revenue was ₹629.23 crore with net profit of ₹199.82 crore

Exceptional Items Context (Previous Year)

For the year ended March 31, 2026, exceptional items totaled ₹49.16 crore, comprising:

  • ₹41.73 crore toward personnel separation cost of field force and marketing teams resulting from an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands: Corex Dx, Corex LS, Dolonex, and Neksium, including personnel separation cost for other support functions
  • ₹7.43 crore increase in provision for employee benefits due to implementation of New Labour Codes by Government of India effective November 21, 2025

Segment Information

The Company has only one segment which is 'Pharmaceuticals'. No segment-wise disclosure is required.

Subsidiary Information

The Company does not have any subsidiary company, associate company, or joint venture company as at June 30, 2026.